RIBON THERAPEUTICS, INC.
- Country
- ๐บ๐ธUnited States
- Ownership
- Holding
- Established
- 2015-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.ribontx.com
Clinical Trials
4
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)โข Click on a phase to view related trials
SAD/MAD Safety and PK Study of RBN-3143 in Healthy and Atopic Dermatitis Subjects
- First Posted Date
- 2022-01-31
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Ribon Therapeutics, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT05215808
- Locations
- ๐ฆ๐บ
Veracity Clinical Research, Woolloongabba, Queensland, Australia
๐ฆ๐บCMAX Clinical Research Pty Ltd, Adelaide, Australia
๐ณ๐ฟOptimal Clinical Trials, Auckland, New Zealand
RBN-2397 in Combination With Pembrolizumab in Patients With SCCL
- Conditions
- Advanced Squamous Non-Small Cell Lung Carcinoma
- Interventions
- First Posted Date
- 2021-11-19
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Ribon Therapeutics, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT05127590
- Locations
- ๐บ๐ธ
Helen F. Graham Cancer Center (Christiana Care), Newark, Delaware, United States
๐บ๐ธCancer Treatment Centers of America, Newnan, Georgia, United States
๐บ๐ธHematology and Oncology Clinic, Baton Rouge, Louisiana, United States
Phase 1 Study of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors
- First Posted Date
- 2019-08-12
- Last Posted Date
- 2023-03-28
- Lead Sponsor
- Ribon Therapeutics, Inc.
- Target Recruit Count
- 130
- Registration Number
- NCT04053673
- Locations
- ๐บ๐ธ
University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
๐บ๐ธSCRI-Denver/HealthOne, Denver, Colorado, United States
๐บ๐ธYale Cancer Center, Yale University, New Haven, Connecticut, United States